BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

...IDH2-positive Ph III Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Samalizumab Anti-CD200 mAb Undisclosed NA Boehringer Ingelheim GmbH BI 836858...
...a total of 10. The first four agents are samalizumab, an anti-CD200 mAb from Alexion; BI 836858...
...IDH2) from Celgene and Agios Pharmaceuticals Inc. Patients with an IDH2 mutation will receive enasidenib. BI 836858...
BioCentury | Oct 24, 2016
Clinical News

Leukemia & Lymphoma Society pipeline update

...They include samalizumab (ALXN6000), an anti- CD200 mAb from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN, Cheshire, Conn.); BI 836858...
...2 (IDH2) from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO, Cambridge, Mass.). BI 836858...
BioCentury | Oct 18, 2016
Top Story

LLS launches collaborative AML trial

...unapproved agents. They include samalizumab (ALXN6000), an anti- CD200 mAb from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN); BI 836858...
Items per page:
1 - 3 of 3